It is a testament to investor success that over 100 exhibitors at CPHI 2026 have some form of PE ownership across the entire ...

Lexeo Therapeutics has signed an agreement to acquire Mantle Therapeutics and launched several new collaborations aimed at ...

AC Immune has reported positive week-100 results from part 1 of its phase 2 VacSyn trial evaluating ACI-7104 in early-stage ...

Grünenthal has entered a new partnership with DKSH to expand access to four established pain medicines across Asia-Pacific.

Johnson & Johnson has reported new long-term data showing that half of patients in early line relapsed or refractory multiple myeloma remained alive and progression-free for at least five years after ...

Ethiopia, Norway and the UK have pledged US$240 million to support CEPI’s five‑year plan to strengthen global readiness for epidemic and pandemic threats. Ethiopia will contin ...

Roche has welcomed MHRA marketing authorisation for Gazyvaro, indicated for adults with moderate to severe, active, autoantibody-positive systemic lupus erythematosus receiving standard therapy. The ...

Axoltis Pharma has reported topline findings from SEALS, its phase 2 study of NX210c in Amyotrophic Lateral Sclerosis. The company said the drug candidate, which aims to restore the blood brain ...

EpilepsyGTx and Viralgen have announced a partnership to advance production of EPY201, EpilepsyGTx’s lead investigational ...

Sanofi and Cheplapharm have announced plans to establish a new strategic partnership that will see Cheplapharm take over 20 mature medicines and three manufacturing sites worldwide. The agreement will ...

GSK has announced that Japan’s Ministry of Health, Labour and Welfare has approved a prefilled syringe presentation of ...

Grünenthal has agreed to acquire Stivarga, an oral treatment for advanced cancers, from Bayer AG for up to €375 million. The company said the deal aligns with its strategy to purchase established ...